Goldstream Capital Management’s AbbVie ABBV Stock Holding History

Goldstream Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,287	Closed	-$294K	–	31
2025 Q4	$294K	Hold	1,287	–	–	0.11%	45
2025 Q3	$298K	Hold	1,287	–	–	0.07%	41
2025 Q2	$239K	Hold	1,287	–	–	0.08%	44
2025 Q1	$270K	Hold	1,287	–	–	0.12%	35
2024 Q4	$229K	Sell	1,287 -1,071	-45%	-$197K	0.06%	37
2024 Q3	$466K	Buy	+2,358	New	+$440K	0.16%	37
2023 Q4	–	Sell	-1,351	Closed	-$201K	–	32
2023 Q3	$201K	Hold	1,351	–	–	0.16%	33
2023 Q2	$182K	Buy	+1,351	New	+$198K	0.13%	35

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldstream Capital Management's ABBV Position: Q1 2026 in Review

Goldstream Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,287 shares — an estimated $294K sold.

Goldstream Capital Management first reported a position in ABBV in Q2 2023 and held it in 8 quarters. The position peaked at $466K in Q3 2024. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Goldstream Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Goldstream Capital Management sold 1,287 AbbVie shares in Q1 2026, an estimated $294K.
Goldstream Capital Management first reported a position in AbbVie in Q2 2023 and held it in 8 quarters.
Goldstream Capital Management's AbbVie position peaked at $466K in Q3 2024.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Goldstream Capital Management's 13F filing for Q1 2026, filed 15 May 2026.